Drug Profile
Ziconotide - ESTEVE Pharmaceuticals/TerSera Therapeutics
Alternative Names: CI 1009; MVIIA; Prialt; SNX 111; SNX 194; Ziconotide acetate - Jazz Pharmaceuticals/ESTEVE PharmaceuticalsLatest Information Update: 07 Apr 2022
Price :
$50
*
At a glance
- Originator Elan Pharmaceuticals
- Developer Eisai Co Ltd; Elan Pharmaceuticals; ESTEVE Pharmaceuticals; Jazz Pharmaceuticals plc
- Class Conotoxins; Neuroprotectants; Non-opioid analgesics; Peptides
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pain
- Discontinued Craniocerebral trauma; Stroke
Most Recent Events
- 06 Nov 2018 Jazz Pharmaceuticals completes the sale of its rights related to ziconotide intrathecal infusion (Prialt) to TerSera Therapeutics in September 2018
- 02 Jul 2018 Jazz Pharamceuticals enters into a definetive agreement to sell rights related to ziconotide intrathecal infusion to TerSera Therapeutics
- 23 Apr 2018 RIEMSER Arzneimittel acquires Ziconotide from Eisai Co Ltd in Europe